WO2018088877A3 - CD66c에 특이적으로 결합하는 항체 및 그의 용도 - Google Patents

CD66c에 특이적으로 결합하는 항체 및 그의 용도 Download PDF

Info

Publication number
WO2018088877A3
WO2018088877A3 PCT/KR2017/012891 KR2017012891W WO2018088877A3 WO 2018088877 A3 WO2018088877 A3 WO 2018088877A3 KR 2017012891 W KR2017012891 W KR 2017012891W WO 2018088877 A3 WO2018088877 A3 WO 2018088877A3
Authority
WO
WIPO (PCT)
Prior art keywords
cd66c
antibody
antibody binding
binding specifically
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/012891
Other languages
English (en)
French (fr)
Other versions
WO2018088877A9 (ko
WO2018088877A2 (ko
Inventor
윤상순
홍권표
김솟을
지길용
임영훈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dinona Inc
Original Assignee
Dinona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11201903800XA priority Critical patent/SG11201903800XA/en
Priority to MX2019005491A priority patent/MX2019005491A/es
Priority to US16/346,259 priority patent/US11220543B2/en
Priority to BR112019009771-6A priority patent/BR112019009771B1/pt
Priority to CA3043691A priority patent/CA3043691C/en
Priority to JP2019547056A priority patent/JP2019535319A/ja
Priority to AU2017358359A priority patent/AU2017358359B2/en
Priority to CN201780070516.5A priority patent/CN110382533B/zh
Priority to EP17869760.3A priority patent/EP3560957A4/en
Application filed by Dinona Inc filed Critical Dinona Inc
Publication of WO2018088877A2 publication Critical patent/WO2018088877A2/ko
Publication of WO2018088877A3 publication Critical patent/WO2018088877A3/ko
Publication of WO2018088877A9 publication Critical patent/WO2018088877A9/ko
Priority to IL266516A priority patent/IL266516B/en
Priority to PH12019501050A priority patent/PH12019501050A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 항-CD66c 항체 및 이의 암 치료 용도에 관한 것으로서, 구체적으로 CD66c를 특이적으로 인식하는 항체를 이용하여 T-세포 활성화, 또는 체액성 면역 반응을 유도할 수 있으며, CD66c를 인식하고 결합하는 항체, 상기 항체 또는 항원결합단편을 코딩하는 핵산분자, 상기 핵산분자를 포함하는 벡터 및 숙주세포 및 상기 항체 또는 항원결합단편의 CD66c 관련 질병, 예를 들면 고형암 경감, 예방, 치료 또는 진단 용도에 관한 것이다.
PCT/KR2017/012891 2016-11-14 2017-11-14 CD66c에 특이적으로 결합하는 항체 및 그의 용도 Ceased WO2018088877A2 (ko)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP17869760.3A EP3560957A4 (en) 2016-11-14 2017-11-14 ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE
US16/346,259 US11220543B2 (en) 2016-11-14 2017-11-14 Antibody binding specifically to CD66c and use thereof
BR112019009771-6A BR112019009771B1 (pt) 2016-11-14 2017-11-14 Ligação de anticorpos especificamente à cd66c e utilização dos mesmos
CA3043691A CA3043691C (en) 2016-11-14 2017-11-14 Antibody binding specifically to cd66c and use thereof
JP2019547056A JP2019535319A (ja) 2016-11-14 2017-11-14 ＣＤ６６ｃに特異的に結合する抗体およびその用途
AU2017358359A AU2017358359B2 (en) 2016-11-14 2017-11-14 Antibody binding specifically to CD66c and use thereof
CN201780070516.5A CN110382533B (zh) 2016-11-14 2017-11-14 特异性结合CD66c的抗体及其用途
SG11201903800XA SG11201903800XA (en) 2016-11-14 2017-11-14 ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2019005491A MX2019005491A (es) 2016-11-14 2017-11-14 Anticuerpo que enlaza especificamente a cd66c y uso del mismo.
IL266516A IL266516B (en) 2016-11-14 2019-05-07 An antibody that specifically binds to cd66c and its use
PH12019501050A PH12019501050A1 (en) 2016-11-14 2019-05-10 ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0151359 2016-11-14
KR20160151359 2016-11-14

Publications (3)

Publication Number Publication Date
WO2018088877A2 WO2018088877A2 (ko) 2018-05-17
WO2018088877A3 true WO2018088877A3 (ko) 2018-10-04
WO2018088877A9 WO2018088877A9 (ko) 2018-11-08

Family

ID=62110206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012891 Ceased WO2018088877A2 (ko) 2016-11-14 2017-11-14 CD66c에 특이적으로 결합하는 항체 및 그의 용도

Country Status (12)

Country Link
US (1) US11220543B2 (ko)
EP (1) EP3560957A4 (ko)
JP (2) JP2019535319A (ko)
KR (1) KR102019032B1 (ko)
CN (1) CN110382533B (ko)
AU (1) AU2017358359B2 (ko)
CA (1) CA3043691C (ko)
IL (1) IL266516B (ko)
MX (1) MX2019005491A (ko)
PH (1) PH12019501050A1 (ko)
SG (1) SG11201903800XA (ko)
WO (1) WO2018088877A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048111T2 (hu) 2015-03-23 2020-05-28 Bayer Pharma AG Anti-CEACAM6 ellenanyagok és alkalmazásuk
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
WO2019221574A1 (ko) * 2018-05-14 2019-11-21 다이노나(주) 골수유래억제세포 관련 질환의 예방 및 치료 용도
US20220010017A1 (en) * 2018-11-14 2022-01-13 Bayer Aktiengesellschaft Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
KR102027248B1 (ko) * 2018-12-14 2019-10-01 건양대학교 산학협력단 유방암 줄기세포 검출용 바이오마커 및 이의 용도
EP3897844B1 (en) 2018-12-19 2023-11-15 Deutsches Krebsforschungszentrum Pharmaceutical combination of anti ceacam6 and tim3 antibodies
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
WO2025237329A1 (en) * 2024-05-15 2025-11-20 Nona Biosciences (Suzhou) Co., Ltd. Ceacam6-binding protein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088521A1 (en) * 2004-03-27 2006-04-27 University Of Arizona Composition and method for cancer treatment
KR20110098593A (ko) * 2010-02-26 2011-09-01 다이노나(주) ＣＤ66ｃ의 폐선암 특이적 에피토프 및 이를 인식하는 항체
US20140099254A1 (en) * 2012-08-14 2014-04-10 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR20160108310A (ko) * 2013-11-25 2016-09-19 씨씨에이엠 바이오세라퓨틱스 리미티드. 암 치료를 위한 항-ceacam1 및 항-pd 항체를 포함하는 조성물
WO2016150899A2 (en) * 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883162B2 (en) * 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8748356B2 (en) * 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
US8404812B2 (en) * 2010-02-26 2013-03-26 Dinona Inc. Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
AR084141A1 (es) * 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
KR101710936B1 (ko) 2014-09-12 2017-02-28 전영권 태양전지 및 그 제조방법
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2017209318A1 (ko) 2016-05-30 2017-12-07 다이노나(주) 탄산탈수소화 효소에 결합하는 항체 및 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088521A1 (en) * 2004-03-27 2006-04-27 University Of Arizona Composition and method for cancer treatment
KR20110098593A (ko) * 2010-02-26 2011-09-01 다이노나(주) ＣＤ66ｃ의 폐선암 특이적 에피토프 및 이를 인식하는 항체
US20140099254A1 (en) * 2012-08-14 2014-04-10 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR20160108310A (ko) * 2013-11-25 2016-09-19 씨씨에이엠 바이오세라퓨틱스 리미티드. 암 치료를 위한 항-ceacam1 및 항-pd 항체를 포함하는 조성물
WO2016150899A2 (en) * 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof

Also Published As

Publication number Publication date
US11220543B2 (en) 2022-01-11
KR102019032B1 (ko) 2019-09-06
EP3560957A2 (en) 2019-10-30
AU2017358359A1 (en) 2019-05-30
WO2018088877A9 (ko) 2018-11-08
IL266516A (en) 2019-08-29
MX2019005491A (es) 2019-08-12
PH12019501050A1 (en) 2019-12-11
WO2018088877A2 (ko) 2018-05-17
BR112019009771A2 (pt) 2019-09-17
CA3043691A1 (en) 2018-05-17
CA3043691C (en) 2022-11-29
US20190263905A1 (en) 2019-08-29
SG11201903800XA (en) 2019-05-30
JP2019535319A (ja) 2019-12-12
KR20180054492A (ko) 2018-05-24
AU2017358359B2 (en) 2021-04-01
EP3560957A4 (en) 2020-10-21
CN110382533B (zh) 2023-09-22
CN110382533A (zh) 2019-10-25
IL266516B (en) 2021-12-01
JP2021177770A (ja) 2021-11-18
JP7450585B2 (ja) 2024-03-15

Similar Documents

Publication Publication Date Title
PH12019501050A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
WO2016191643A3 (en) Tigit-binding agents and uses thereof
PH12017500890A1 (en) Antibody drug conjugates
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
HK1252666A1 (zh) 针对cd40的抗体
GEP20217220B (en) Pd1 and/or lag3 binders
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
HK1254861A1 (zh) 抗lag3抗体及其用途
WO2014118236A3 (en) High avidity binding molecules recognizing mage-a1
CA2856895C (en) Anti-pd-l1 antibodies and uses thereof
JO3739B1 (ar) روابط ctla4
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2015118175A3 (en) TARGETED TGFβ INHIBITION
WO2018031490A3 (en) Anti-ox40 binding proteins
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2014163714A3 (en) Antibody drug conjugates
EP4696785A3 (en) Anti-pd-1 antibodies
WO2018069871A3 (en) Anti-kras binding proteins
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2015184403A3 (en) Anti-epidermal growth factor receptor (egfr) antibodies
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
WO2015187521A3 (en) Anti-blys antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17869760

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3043691

Country of ref document: CA

Ref document number: 2019547056

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019009771

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017358359

Country of ref document: AU

Date of ref document: 20171114

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017869760

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112019009771

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190514